Loading…
Poland's largest medical diagnostics laboratory chain, providing lab testing and diagnostic imaging services nationwide.
Poland's largest medical diagnostics laboratory chain, providing lab testing and diagnostic imaging services nationwide.
Paid either by the national health fund under contracts with set volumes, or directly by private patients and employers; lab tests are the bulk of the work, with imaging and genetics on top. It has grown mostly by buying smaller laboratories in a fragmented Polish market.
In one line: Poland's largest medical diagnostics lab chain, like a Polish Quest Diagnostics.
Moat: narrow (scale, distribution, brand). Largest diagnostic lab network in Poland with scale and NFZ contract relationships.
Headquarters: Krakow, Poland · Founded: 2001 · Employees: 7,635
Size Diagnostyka (DIA.WA) is a Poland Health Care company (Medical/Nursing Services) with a market value of $1.29B, the 35th largest of 83 Poland companies the cockpit tracks. Shares closed at PLN 150.00 on 6 Nov 2026.
Performance Over six months the shares fell 4.6%, against +21.3% for the median peer and +14.3% for the Poland market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 19.2% over the last twelve months (peer median +7.3%); the operating margin is 14.5% (peer median 5.0%).
Valuation It trades at 18.4× forward earnings against a peer median of 30.4× (5th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.1 points above its cost of capital (9.3% WACC).
Next results Next results expected around 26 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | PLN 2.58B | PLN 2.41B | PLN 1.95B | PLN 1.59B | PLN 1.44B |
| Revenue growth | — | +24% | +23% | +11% | — |
| Gross profit | PLN 433M | PLN 429M | PLN 355M | PLN 265M | PLN 278M |
| EBITDA | PLN 596M | PLN 581M | PLN 481M | PLN 378M | PLN 362M |
| Net income | PLN 255M | PLN 252M | PLN 223M | PLN 123M | PLN 167M |
| Free cash flow | PLN 251M | PLN 281M | PLN 229M | PLN 214M | PLN 177M |
| Capital expenditure | PLN 202M | PLN 205M | PLN 133M | PLN 81.3M | PLN 89.4M |
| Total debt | PLN 1.22B | PLN 1.08B | PLN 969M | PLN 850M | PLN 721M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Diagnostyka DIA.WA | $1.29B | -5% | +19% | 15% | 18.4× | 6.9% |
| Medicover MCOV-B.ST | $4.14B | +36% | +6% | 7% | 38.3× | 20.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DIA.WA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.5% | +5.9% | 4th lowest of 21 |
| 6-month return | -4.6% | +21.3% | 5th lowest of 21 |
| Distance from 52-week high | -27.9% | -16.0% | 4th lowest of 21 |
| Revenue growth (TTM) | +19.2% | +7.3% | 6th highest of 21 |
| Operating margin | 14.5% | 5.0% | 5th highest of 21 |
| Forward P/E | 18.4× | 30.4× | 5th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 6.9% | 15.7% | 6th least demanding of 17 |
| Growth delivered (Del g) | +18.9% | +11.8% | 5th highest of 17 |
| Hurdle (Req g minus delivered) | -12.0 pp | +4.3 pp | 3rd least demanding of 17 |
| ROIC minus cost of capital | +8.1 pp | -3.7 pp | 3rd highest of 20 |
| EV / EBITDA | 10.6× | 16.8× | 8th cheapest of 17 |
| Net debt / EBITDA | 2.0× | 1.3× | 8th most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 18.4× | 6.9% | +18.9% |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | n/a | n/a | n/a |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 18.6× | n/a | n/a |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% | +2.1% |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 7.2× | -19.5% | +253.5% |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 10.4× | 6.8% | +7.7% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% | +8.2% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |